A Deeper Look into Newer CDK 4/6 Inhibitors in the
Management of HR+, HER2- Advanced
Breast Cancer: Insight into Clinical
Activity and Safety Profiles

A continuing medical education activity sponsored by NAMCP and AAMCN.

New Agents and Emerging Strategies in the Management of Hormone Receptor-Positive (HR+) Advanced Breast Cancer: Inhibiting Cellular Signaling Pathways for Improved Therapeutic Outcomes is a 3-part live webinar series that will provide attendees with the latest information in Breast Cancer.

This is Part 2 of the series focusing on clinical activity and safety profiles

This activity is an archive from the webinar held December 13, 2017

This activity is valid from January 20, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Novartis Pharmaceuticals and Pfizer

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2017. The incidence in women in the United States is 1 in 8. About 40,290 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Fortunately for advanced breast cancer patients with hormone receptor-positive (HR+) advanced breast cancer, several new agents have recently become available or are undergoing late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HR+, HER2- metastatic breast cancer. This activity will attendees with the appropriate use of new therapies, such as CDK 4/6 inhibitors, through a shared decision-making approach for the treatment of HR+, HER2- metastatic breast cancer, and a solid understanding of the mechanism of action of these therapies. This webinar will be part two of a three-part webinar series that will look closely at HR+, HER2- advanced breast cancer.

Upon Completion of this activity, participants will be able to:

  • Review the mechanisms of action of current and emerging CDK 4/6 inhibitor treatment options and in the management of HR+, HER2- advanced breast cancer

  • Analyze recent safety and efficacy data of current and emerging CDK 4/6 inhibitors for HR+, HER2- advanced breast cancer

  • Identify and select combination therapy with CDK 4/6 inhibitors and endocrine therapy agents in patients with hormone receptor-positive breast cancer

  • Discuss the role of CDK 4/6 inhibitors in the first-line management of HR+, HER2- advanced breast cancer

Faculty: Sara Hurvitz, MD, FACP
Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA


Sara Hurvitz, MD received grants for clinical research from: Amgen, Bayer, Biomarin, Boehringer Ingelheim, Cascadian, Dignatana, Genentech; GlaxoSmithKline, Lilly USA, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Puma, Roche, Seattle Genetics. Received Travel from: Bayer, Lilly USA, OBI Pharma, Novartis. Her Presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Novartis Pharmaceuticals and Pfizer

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue